Trial Profile

PHASE 1, OPEN-LABEL STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF DS-8273A IN SUBJECTS WITH ADVANCED SOLID TUMORS OR LYMPHOMAS

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DS 8273 (Primary)
Indications Lymphoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors Daiichi Sankyo Inc

Most Recent Events

05 Apr 2017 Results (n=16) presented at the 108th Annual Meeting of the American Association for Cancer Research
03 Jan 2017 Results published in the Investigational New Drugs
13 Dec 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com